Application 125559
- Type
- BLA
- Sponsor
- SANOFI AVENTIS
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 125559 | Praluent | alirocumab | 351(a) | Rx | 2026-06-01 |
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | PRALUENT | ALIROCUMAB | INJECTABLE;INJECTION | 75MG | Yes | No |
| 002 | PRALUENT | ALIROCUMAB | INJECTABLE;INJECTION | 150MG | Yes | No |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Praluent | ALIROCUMAB | Regeneron Pharmaceuticals, Inc. | 7bcfbac2-e8ac-4569-8edc-bcde3b1fd172 | 2026-07-16 | Warnings, Adverse reactions | BLA125559 61755-021 61755-020 |
| Praluent | ALIROCUMAB | Sanofi-Aventis U.S. LLC | 446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4 | 2026-07-07 | Warnings, Adverse reactions | BLA125559 0024-5903 0024-5901 0024-5904 0024-5902 |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 61755-020 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-020 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-020 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-020 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-020 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-021 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-021 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-021 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-021 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-021 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 83852 | SUPPL | 2025-10-21 |
| 83770 | SUPPL | 2025-10-15 |
| 77774 | SUPPL | 2024-03-11 |
| 77772 | SUPPL | 2024-03-08 |
| 66986 | SUPPL | 2021-04-02 |
| 66985 | SUPPL | 2021-04-02 |
| 66973 | SUPPL | 2021-04-02 |
| 66972 | SUPPL | 2021-04-02 |
| 62127 | SUPPL | 2020-03-11 |
| 62113 | SUPPL | 2020-03-11 |
| 58473 | SUPPL | 2019-04-30 |
| 58472 | SUPPL | 2019-04-30 |
| 58464 | SUPPL | 2019-04-29 |
| 58463 | SUPPL | 2019-04-29 |
| 57158 | SUPPL | 2019-01-09 |
| 56468 | SUPPL | 2018-11-15 |
| 56381 | SUPPL | 2018-11-08 |
| 55315 | SUPPL | 2018-08-24 |
| 55278 | SUPPL | 2018-08-23 |
| 55035 | SUPPL | 2018-07-30 |
| 49837 | SUPPL | 2017-09-22 |
| 49819 | SUPPL | 2017-09-21 |
| 49646 | SUPPL | 2017-08-31 |
| 49179 | SUPPL | 2017-08-02 |
| 48138 | SUPPL | 2017-04-27 |
| 48099 | SUPPL | 2017-04-25 |
| 22824 | ORIG | 2015-08-28 |
| 31997 | ORIG | 2015-07-27 |
| 18937 | ORIG | 2015-07-24 |